<?xml version="1.0" encoding="UTF-8"?>
<p id="para0014">There are two phase 3, randomised, double-blind, placebo-controlled multicentre clinical trials currently ongoing in China. These trials have been submitted to ClinicalTrials.gov on 31 January 2020 and are designed to evaluate the efficacy and safety of parenteral remdesivir in hospitalised adults with mild-to-moderate and severe COVID-19, i.e. NCT04252664 (
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04252664" id="interref0002" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04252664</ext-link>) and NCT04257656 (
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04257656" id="interref0003" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04257656</ext-link>), respectively. The number of cases planned to be enrolled is 308 and 452, respectively. A 10-day regimen of remdesivir treatment is as follows: 200 mg loading dose on Day 1, followed by 100 mg once-daily maintenance doses for 9 days in both studies. The former regimen of remdesivir therapy was used in the randomised clinical trial of Ebola virus disease 
 <xref rid="bib0023" ref-type="bibr">[23]</xref>.
</p>
